Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an update.
Rhythm Biosciences has announced a proposed issue of up to 18,834,007 new fully paid ordinary shares, to be conducted as a placement or other form of security issue. The new securities are expected to be issued on 23 April 2026, signalling a planned capital raising that could provide additional funding for the company’s operations and strategic initiatives, with potential dilution for existing shareholders but added financial flexibility for future growth.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.18 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd. is an ASX-listed biotechnology company operating under the ticker RHY. The company is focused on developing and commercialising diagnostic solutions in the biosciences sector, targeting healthcare and medical markets through its range of securities listed on the Australian Securities Exchange.
Average Trading Volume: 955,296
Technical Sentiment Signal: Buy
Current Market Cap: A$61.79M
For a thorough assessment of RHY stock, go to TipRanks’ Stock Analysis page.